Depression
Wyeth Provides Regulatory Update Regarding Desvenlafaxine for the Treatment of Major Depressive Disorder
Published in Food and Drug Law Weekly, October 31st, 2008
Desvenlafaxine has already been approved for the treatment of MDD in adults in the United States, Australia and Brazil, and applications are currently pending in 22 markets. As part of its global regulatory strategy, and in consultation with the Committee for Medicinal Products for Human Use of the European Medicines Agency, the Company has chosen not to pursue its central European Marketing Authorisation Application at this time. Wyeth remains committed to making desvenlafaxine...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
More Articles from Food and Drug Law Weekly
- American Association for Justice
FOIAs Reveal How Bush Administration Made Complete Immunity for Negligent Corporations a Top Priority - Mental Health
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSEŽ (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD - Nausea
Wyeth v. Levine: Preemption and the Facts - Women's Health
Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court - AccuDial, Inc.
FDA Cites Dosing Errors in New Recommendations for Children's OTC Medications - Adverse Drug Reactions
New adverse drug reactions study findings have been reported by scientists at Food & Drug Administration - More from this issue of Food and Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
